FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to infectology and cardiology, and can be used to determine the risk of developing cardiovascular complications in COVID-19. In the blood serum of a patient with confirmed COVID-19, a laboratory determination of the content of endothelin-1 is carried out using a quantitative enzyme immunoassay. Depending on the value obtained, the degree of risk of developing cardiovascular complications is established in accordance with the following division: less than 0.16 pmol/l - low risk; from 0.16 to 0.5 pmol/l - medium risk; from 0.5 to 2.0 pmol/l - high risk; more than 2.0 pmol/l - a very high risk.
EFFECT: method provides the possibility of establishing the risk levels of developing cardiovascular complications in COVID-19: low, medium, high, very high, regardless of the presence or absence of a history of chronic somatic pathology of the circulatory system, by determining endothelin-1 in blood serum, which is a marker of endothelial dysfunction.
1 cl, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DETERMINING THE RISK OF DEVELOPING ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION FOR 18 MONTHS AFTER A NEW CORONAVIRUS INFECTION (COVID-19) | 2024 |
|
RU2835912C1 |
| METHOD FOR DETERMINING RISK OF DEVELOPING ACUTE CEREBROVASCULAR ACCIDENT IN PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION FOR 12 MONTHS AFTER COVID-19 | 2023 |
|
RU2826593C1 |
| METHOD FOR DETERMINING THE RISK OF DEVELOPING CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH STAGE II ESSENTIAL ARTERIAL HYPERTENSION WITHIN 12 MONTHS AFTER COVID-19 | 2021 |
|
RU2767624C1 |
| METHOD FOR PREDICTING RISK OF DEATH AT HOSPITAL STAGE IN PATIENTS WITHOUT ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION WHO HAVE UNDERGONE NEW COVID-19 CORONAVIRUS INFECTION, TAKING INTO ACCOUNT THEIR IMMUNOLOGICAL STATUS | 2022 |
|
RU2781565C1 |
| METHOD OF TREATMENT OF PATIENTS WHO HAVE HAD NEW CORONAVIRUS INFECTION WITH LUNG DAMAGE IN THE EARLY RECOVERY PERIOD | 2022 |
|
RU2801234C1 |
| METHOD FOR PREDICTION OF UNFAVORABLE OUTCOME OF DISEASE IN CORONAVIRUS INFECTION | 2023 |
|
RU2835545C1 |
| METHOD FOR ASSESSING THE RISK OF DEVELOPING A SEVERE COURSE OF CORONAVIRUS INFECTION IN WOMEN | 2021 |
|
RU2761138C1 |
| METHOD FOR DETECTING VASCULAR ENDOTHELIUM INVOLVEMENT | 2021 |
|
RU2766781C1 |
| METHOD OF PREDICTING THE RISK OF DEVELOPING CHRONIC HEART FAILURE IN PATIENTS WHO HAVE HAD A NEW CORONAVIRUS INFECTION COVID-19 | 2023 |
|
RU2805601C1 |
| METHOD FOR ASSESSING THE RISK OF DEVELOPING A SEVERE COURSE OF CoVID-19 | 2022 |
|
RU2782796C1 |
